Form 4 for CHRS Coherus Oncology, Inc.
Accepted 2022-01-06 00:00:00 ET · period of report 2022-01-04 · accession 0001567619-22-000821 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-06 | 2022-01-04 | CHRS | Lanfear Dennis M | Pres, CEO, Dir | A - Grant | $0.00 | +86.2K | 579.5K | +17% | $0 |
| D | 2022-01-06 | 2022-01-04 | CHRS | Lanfear Dennis M | Pres, CEO, Dir | A - Grant | $0.00 | +402.5K | 402.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-04 | A | A | 86,250 | $0.00 | 579,508 | D | — | — | (F1) Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 4 of each year, with the first 1/3 vesting on January 4, 2023 and with the RSUs being fully vested on January 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. (F2) Includes 86,250 RSUs. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-01-04 | A | A | 402,500 | $0.00 | 402,500 | D | $15.94 · — to 2032-01-04 | 402,500 Common Stock | (F5) The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |